Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
economic reasons
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| BioTeSys GmbH | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
This Post-Market Clinical-Follow Up (PMCF) study gains data on the efficacy and safety of "Alflorex bei Reizdarm", a probiotic based on Bifidobacterium longum 35624, in the daily use by irritable bowel syndrome (IBS) patients. The aim of this study is the observation of the influence of "Alflorex bei Reizdarm" on typical symptoms, severity score and quality of life of IBS patients in medical practice and everyday use.
This Post-Market Clinical-Follow Up (PMCF) study observes adult patients with irritable bowel syndrome (IBS) which receive "Alflorex bei Reizdarm", a probiotic based on Bifidobacterium longum 35624, for 8 weeks by recommendation of their physician. IBS symptoms are recorded on a weekly basis by the participants. IBS severity score, interference with general life and safety parameters are also recorded. Primary objective is the assessment of the change in overall IBS symptoms (sum of abdominal pain, bloating, gas, difficulty in defecating/constipation and urgency/diarrhoea).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Bifidobacterium longum 35624 | Other | 1 capsule daily |
| Measure | Description | Time Frame |
|---|---|---|
| Relative change in overall IBS symptoms compared to day 1 (sum of abdominal pain, bloating, gas, difficulty in defecating/constipation and urgency/diarrhoea symptom scores) | rated by participant on a 6-point Likert scale (from 0 "no symptoms" to 5 "very severe") | assessed weekly over 8 weeks (from day 1 to day 57) |
| Measure | Description | Time Frame |
|---|---|---|
| Relative change in the individual IBS symptoms abdominal pain, gas, bloating, difficulty in defecating/constipation and urgency/diarrhoea compared to day 1 | rated by participant on a 6-point Likert scale (from 0 "no symptoms" to 5 "very severe") | assessed weekly over 8 weeks (from day 1 to day 57) |
| Severity score of irritable bowel syndrome compared to day 1 |
Not provided
Inclusion Criteria:
Adult, diagnosed IBS patients with typical IBS symptoms (abdominal pain, bloating, gas, constipation or diarrhea) and physician's recommendation to take the study medication (probiotic with B. longum 35624) for 8 weeks
Exclusion Criteria:
-
Not provided
Not provided
Not provided
IBS patients of general practicioners and gastroenterologists
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Several General Practicioner and Gastroenterologists (Multicentric) | Düsseldorf | North Rhine-Westphalia | Germany |
Not provided
| ID | Term |
|---|---|
| D043183 | Irritable Bowel Syndrome |
| ID | Term |
|---|---|
| D003109 | Colonic Diseases, Functional |
| D003108 | Colonic Diseases |
| D007410 | Intestinal Diseases |
| D005767 | Gastrointestinal Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
German IBS severity scoring system questionnaire by the participant (IBS-SSS, scoring from 0 to 500; higher scores indicating higher severity of IBS symptoms) |
| assessed at day 1, day 29 and day 57 |
| Efficacy & tolerability by physician | rated on a 6-point Likert scale (from 1 "very good" to 6 "unsatisfactory") | assessed at day 57 |
| Efficacy & tolerability by participant | rated on a 6-point Likert scale (from 1 "very good" to 6 "unsatisfactory") | assessed at day 57 |
| Interference of IBS symptoms with general life | rated by the participant by question 5 of the German IBS-SSS questionnaire (scoring from 0 to 100; higher scores indicating higher interference with general life) | assessed at day 1, day 29 and day 57 |
| D004066 | Digestive System Diseases |